Kidney International Reports (Apr 2021)
POS-318 PATIENT PREFERENCES FOR RISKS AND BENEFITS OF MEDICATIONS TO MANAGE ANEMIA OF CHRONIC KIDNEY DISEASE: A DISCRETE CHOICE EXPERIMENT
- J.J. GARCIA SANCHEZ,
- S. Fifer,
- B. West,
- E. Wittbrodt,
- P. Bhatt,
- S. Grandy,
- N. Rao,
- D. Wong,
- R. Karamy,
- A. Parackal,
- F. Khan,
- K. Tennankore,
- D. Johnson
Affiliations
- J.J. GARCIA SANCHEZ
- AstraZeneca, Global Pricing and Market Access, Cambridge, United Kingdom
- S. Fifer
- Community and Patient Preference Research, Research and Innovation, Sydney, Australia
- B. West
- Community and Patient Preference Research, Research, Sydney, Australia
- E. Wittbrodt
- AstraZeneca, Biopharmaceuticals Medical, Gaithersburg, United States
- P. Bhatt
- AstraZeneca, Biopharmaceuticals Medical, Wilmington, United States
- S. Grandy
- AstraZeneca, Global Pricing and Market Access, Gaithersburg, United States
- N. Rao
- AstraZeneca, Global Pricing and Market Access, Cambridge, United Kingdom
- D. Wong
- AstraZeneca, Innovation- Value & Access Strategy, Mississauga, Canada
- R. Karamy
- AstraZeneca, Market Access and Pricing, Sydney, Australia
- A. Parackal
- AstraZeneca, Innovation- Value & Access Strategy, Mississauga, Canada
- F. Khan
- AstraZeneca, Biopharmaceuticals Medical, Gothenburg, Sweden
- K. Tennankore
- Dalhousie University- Halifax, Department of Medicine, Nova Scotia, Canada
- D. Johnson
- Australasian Kidney Trials Network- University of Queensland, Faculty of Medicine, Brisbane, Australia
- Journal volume & issue
-
Vol. 6,
no. 4
pp. S136 – S137
